References
- Kim JY, Kwon O. Garlic intake and cancer risk: an analysis using the Food and Drug Administration's evidence-based review system for the scientific evaluation of health claims. Am J Clin Nutr. 2009 ; 89 : 257-64.
- Mbulaiteye SM, Hisada M, El-Omar EM. Helicobacter Pylori associated global gastric cancer burden. Front Biosci. 2009 ; 14 : 1490-4.
- A joint compilation committee of the college of oriental medicine in Korea. Herbology(5th edition). Seoul : Younglimsa. 1999 : 498-9.
- Kang KH, Youn HM. Study on anti-allergic effecst of ganoderma lucidum herbal acupuncture and ganoderma lucidum extract. Journal of Pharmacopuncture 2007 ; 10(3) : 37-46. https://doi.org/10.3831/KPI.2007.10.3.037
- Kon Ga. A study on Cancer and Lump. Seoul: Sungbosa. 1984 : 25-7.
- Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH. Premature p34cdc2 activation required for apoptosis. Science. 1994; 263 : 1143-5. https://doi.org/10.1126/science.8108732
- Evans VG. Multiple pathways to apoptosis. Cell Biol Int. 1993 ; 17 : 461-76. https://doi.org/10.1006/cbir.1993.1087
- Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res. 2001 ; 7 : 95-106. https://doi.org/10.1007/BF03032574
- Timmer T, de Vries EG, de Jong S. Fas receptor-mediated apoptosis: a clinical application? J Pathol. 2002 ; 196 : 125-34. https://doi.org/10.1002/path.1028
- LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003 ; 10 : 66-75. https://doi.org/10.1038/sj.cdd.4401187
- Belka C, Jendrossek V, Pruschy M, Vink S, Verheij M, Budach W. Apoptosis-modulating agents in combination with radiotherapy- current status and outlook. Int J Radiat Oncol Biol Phys. 2004 ; 58 : 542-54. https://doi.org/10.1016/j.ijrobp.2003.09.067
- Nikiforos K, Kontogeorgos G. Bcl-2 Gene family in endocrine pathology: a review. Endocr Pathol. 2000 ; 11 : 205-13. https://doi.org/10.1385/EP:11:3:205
- Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol. 2006 ; 3 : 388-98. https://doi.org/10.1038/ncponc0538
- Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun. 2003 ; 304 : 437-44. https://doi.org/10.1016/S0006-291X(03)00615-6
- LaCasse EC, Baird S, Korneluk RG, Mac-Kenzie AE. The inhibitors of apoptosis(IAPs) and their emerging role in cancer. Oncogene. 1998 ; 17 : 3247-59.
- Checinska A, Hoogeland BS, Rodriguez JA, Giaccone G, Kruyt FA. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy- induced apoptosis by enhancing caspase- 3 activation. Exp Cell Res. 2007 ; 313 : 1215-24. https://doi.org/10.1016/j.yexcr.2006.12.011
- Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell. 2001 ; 104 : 781-90.
- Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998 ; 58 : 5315-20.
- Rao L, White E. Bcl-2 and the ICE family of apoptotic regulators: making a connection. Curr Opin Genet Dev. 1997 ; 7 : 52-8. https://doi.org/10.1016/S0959-437X(97)80109-8
- Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005 ; 11 : 3974-86. https://doi.org/10.1158/1078-0432.CCR-04-2661
- Muller S, Briand JP, Barakat S, Lagueux J, Poirier GG, De Murcia G, et al. Autoantibodies reacting with poly(ADP-ribose) and with a zinc-finger functional domain of poly(ADP-ribose) polymerase involved in the recognition of damaged DNA. Clin Immunol Immunopathol. 1994 ; 73 : 187-96. https://doi.org/10.1006/clin.1994.1187
- Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA- inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995 ; 81 : 801-9. https://doi.org/10.1016/0092-8674(95)90541-3
- Nicotera TM, Privalle C, Wang TC, Oshimura M, Barrett JC. Differential proliferative responses of Syrian hamster embryo fibroblasts to paraquat-generated superoxide radicals depending on tumor suppressor gene function. Cancer Res. 1994 ; 54 : 3384-8.
- Randerath K, Randerath E, Smith CV, Chang J. Structural origins of bulky oxidative DNA adducts(type II I-compounds) as deduced by oxidation of oligonucleotides of known sequence. Chem Res Toxicol. 1996 ; 9 : 247-54. https://doi.org/10.1021/tx950085v
- Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000 ; 407 : 390-5. https://doi.org/10.1038/35030140
- Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991 ; 51 : 794-8.
- Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ. Phosphatidylinositol 3-kinase is an early intermediate in the G beta gammamediated mitogen-activated protein kinase signaling pathway. J Biol Chem. 1996 ; 271 : 12133-6. https://doi.org/10.1074/jbc.271.21.12133
- Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996 ; 87 : 619-28. https://doi.org/10.1016/S0092-8674(00)81382-3